Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
this co could have turned a profit on $5m a year revs
snake oil products sold under a negative option billing agreement combined with money is no object marketing costs is a loosing business model
they could generate $50m in sales and still spend $62m to do it
anybody can do that
the execs get a big fat paycheck and the directors get their money for doing nothing
its a scam
i dont see any runup into some great fri ah earnings report
got offers bigger than this vol
one year ago today it hit .663
that was pops offer
he should have walked away that day
lesson learned
congrats youve discovered the negative option marketing ploy of damajes platform
aka beyond reason
their motto should be
innovus were with you for life!
lol
doesnt matter if it was good they would be pumping it
2.4m revs and 2m loss is my guess
(.012) on 165m
$1m per month in costs unbelievable
sec needs to audit this scam
pick up under .13 and i will pm you when i release the stranglehold
you have been right more than anyone else here
least i can do
innv .116 -4.13% on 203065 vol
they just run from the offers
looks like medical device tricked a few indeed
finally got rid of some
q2 gonna be yuge! lol
funny nobody talking about how much theyre buying
false confidence
these arent the droids youre looking for
half the company at a 25% discount to market including 5 year warrants
who does this?
and nobody will bite step in and replace him because the business model is garbage
what happened to the generics ms liu?
fluticare? tadalafil? floranex? remember?
what happened novalere?
you guys paid $6.5m what for?
how those alervaxsmack sales?
yes lets add more to the enemy making outrageously priced recurring billing nightmare sales platform
at least we have that free no cost or obligation labeling license with hikma right?
the info you brought to light was enough
name changes from original 9 members
this ayme-jouve ringleader
docs that show less than $1b capital
heres one from 2014
http://schneider-brothers.co.uk/html/2014%2012%2031%20Accounts%20with%20SBP%20shares.pdf?PHPSESSID=2tps1trikjt8cj8sjthb4j1fd3
the fact that sungames is about the only other deal to be found
looks like junior vulture financing to me
do you really think the vcs holding .25 resets are going to wait for big bucks on development with no funding?
nemus cant afford the electric bill much less lawyers
ill be glad to pump any good news that comes along but realistically?
doubts
i think i get the game here from poking around at schneider deals
they make a deal with cos that have share overhead and depressed mc
if the deal announcement succeeds in clearing out the overhead and freeing up room for their dilution they close and fund
that did not happen here the .25s are still trickling out
its bait and switch financing
nemus has no cash and i suspect not the will to pnd shneiders $ to their liking
the catalent contract will not start without funding imo
nothing will progress without cash
low .20s after the q i fear
board suspension is not jailhouse
honey can flag all the posts she wants wont change anything
couldnt give a rats ass anyway
pass the courvoisier
no halt for news or approvals sorry
if your shares are in a margin not cash account they can be borrowed against regardless of open orders
last secfilings.com piece was june 13
last insider financial piece was may 13
damaje may have put the breaks on pump marketing
no useless prs in weeks
may try and paint rosey picture going forward
but if sales were good they would be pre hyping the q #s
i expect flat or (.01) and many pats on the back
then there is the mystery half the co at .15
no closure no disclosure
almost time for shawns q2 tell all
os should be 155m
Very much appreciated
if the financing is shaky at least the pipeline is solid
ill try to look into other deals with schneider when i get time
wait it out
i agree
i guess just a clear sign of how much red murphy inherited
always inching closer to possible buyout so ill hold too
thanks again some great dd
oh lord!
yes vinpat please!
i saw that philippe name in those horrid glass door reviews
i dont even want to google the full name and look now
corporationwiki says
John Severson
610 Newport Center Dr Newport Beach, CA 92660
— Previous Manager for Schneider Finance LLC
looks like some local shenanigans
whats murphy up to?
at least do a lincoln park or asher deal so we know what were up against lol
anybody else got thoughts?
come on chico tell us what we dont know
asset and wealth management could very well mean helping clients unload past preferred arrangements
ive never liked those .25 resets
i suppose a heavy pump n dump campaign would accompany that and ive always been prepared to unload on a good pop so i still hope it comes
schneider just doesnt look completely on the up and up to me
i dont like anything im digging up
i may rethink strategy here
thank you for bringing it up
from scamguard.com
Total scam alright....They started this scam in 2010......Nobody ever got 3D tablets...They got people to invest saying you would get a tablet if you invest 1K and then when SUNGAME Corp is bought by Schneider Brothers INC investment company in the UK for $100 Million USD..you would then get 1000% return on investment..........SUNGAME hasnt filed financials in over three years with the SEC...........The company based on the current share price and outstanding shares is barely worth a few million. Neil Chandran was CEO of SUNGAME until the SEC forced him to resign as CEO in 2015. He was to also banned from ever trading securities or being a director of any corporation. Yet Neil keeps pitching the sale of a company he isnt a director of.........There have been NO SEC fillings in regards to any sale of SUNGAME.
Neil , Eric Madsen, Novia Mclymont, Angella Robinson, Sayyid Campbell, Robert Guy and Andrew Montague have been running this scheme...........No one has gotten their money back. Google Neil Chandran and see what a fraudster he is...................................They have stopped doing conference calls and the weekly updates are down to one a month........Wonder how any millions they have stolen from people? Rumor is the SEC is onto them. I hear couple of them have started a new MLM scam..Be warned folks.
yikes!
bloomberg says
SB Securities S.A. operates as a subsidiary of Sberbank of Russia OJSC.
and look at the names of most of those office directors comrade
little nervous too now
im just assuming they report all figures except shares in 1000s like us small caps
it certainly looks odd like what happened to 70m in assets in a year
perhaps converted to capital and reallocated and not reported until 2017?
its uk so way beyond my paygrade too
perhaps compare your finding with what crunchbase.com says as far as moving from switzerland in 1991
some of your findings do look dubious indeed
notice the different websites for shneider-brothers and schneider-securities and their office in newport beach ca
maybe call or write
ADMINISTRATIVE ASSISTANT Newport Beach, U.S.A.: Priscilla LENKE
E-mail: priscilla@schneider.finance - Telephone: (+1) 949 706 31 32
and she will straighten it all out for us
she looks friendly!
its x1000
In 2016, the Group's total net assets are approximately £ 407 million, and the total amount of capital under management is approximately £ 707 million. In 2016, the Group issued about EUR 100 million of financial guarantees. Those guarantees are fully backed up and secured on the Group's Assets.
post more links to name changes etc please but for now i think youre being a wee bit paranoid
an ind is forthcoming imo
got it with this link
https://s3-eu-west-1.amazonaws.com/document-api-images-prod/docs/KFJS1QL_3YKK8wDxLnbkFpjTutxdd-a9IL-xIpI-rpc/application-pdf?AWSAccessKeyId=ASIAJF5G7NHBJMKTVHQA
i havnt a clue
suspect nemus didnt come through with a milestone
at least they updated timely
not too much pain for the vol
we want to see an ind filed and fda clearance on a p2b efficacy trial of <6 months for this indication in line with 502(b)(2) submission
approval by 2019
$660m in first 3 years of approved usage
$8 by 2018 and $26 by 2020
nothing less will do
nite is usually the ax
google market maker ax
the 3 cs cdel cant and csti are always in play
etrf is etrade adtf is ameritrade both mostly retail
vndm and vfin play when things are hot or they have lots of shares to sell
all mm take orders from inside/insty clients and feed dilution
if 3 cs are on top of book dont trade
wait until etrf shows up
about all i can say on book trading
experience is king
glty
ps- nobody naked shorts otc stocks
otcshortreport.com is bs because it includes riskless principal trades
mms keep inventories and sell rpt all day
always weigh volume vs price when trading
nothing but fills
avg down to .38 from .52 on 165k
did you work today murphy?
have it your way
bring on the vol
imo its not the schneider shares but the approx 8m reset preffs
or whatever the #
those .25s will slowly trickle in at the vwap
a major catalyst could blow them out in a few days of 1m+ vol
schneider may be looking for $2+ for their return
going into human trials with <100m o/s will be nice
there shouldnt be an issue as the co stated it was a mfg who already produced the rx version
no the fda does not disclose any info unless the co already has and it is material safety or other consumer awareness stuff
if they got a clr they would report it
all speculation anyway the point is the co could have said something and been far more transparent
dont trust the market dont marry stocks
steal your $ fair and square
got the book stacked
if this breaks either way i am getting fills
enough of this pokey!
yes this type of submission should not receive a clr unless the manufacturer cannot get inspection clearance or does not correct deficiencies on time
high tech india may have submitted and gsk followed with a patent infringement challenge
https://www.drugpatentwatch.com/p/generic-api/FLUTICASONE+PROPIONATE
so perhaps innv just outright bought another license from ww and hopes to generate enough revenue over that time span to sue gsk for d a m a j e s !
for andas generally its a refuse to receive response and the co dots the i and resubmits at $25k per and waits 3 months again for fda to pick it up and 3 months later they get another rtr
about 8 months total between cycles so fc might have got 3 and the fourth caused them to do the side deal
if q2 numbers are bad theyre going to be brutally so
if theyre improving it might cause a .01 profit and then the new promo scheme will be full on
earlier than projected cash flow positive!
on track for .03-.04 this year!
fluti marketing plan in full swing like nothing happened!
damaje didnt overstate the projection it just didnt come and he hasnt and probably wont acknowledge unless the anda is abandoned and withdrawn/inactivated
then he will issue some boilerplate pr and the market will be going yeah no shit sherlock
again shawn was doba about q2 lol
they can defer some huge expenses and make it look good for a q so the dilution shares can get out there
then they can pass an r/s vote on broker non vote exclusion
refuse to receive and refuse to file are examples of replies that cause a need to resubmit which starts a 6 month review cycle
a clr means its dead and the entire anda needs to be refiled with another $200k filing fee
you only get one clr and most cause the abandonment of the approval attempt
did you read the pdf?
Moreover, it is our view that the majority of applicants disclose to the public—usually via press releases and annual financial reports—when an application for a new product or significant new indication has been submitted, approved or withdrawn. This is especially common practice for products that are new molecular entities.
innv announced the submission
The over-the-counter Abbreviated New Drug Application (ANDA) for the product was filed with the U.S. Food & Drug Administration during the fourth quarter of 2014. In January of 2015, the FDA accepted the ANDA for review and the application has been making its way through the lengthy approval process. The good news is that ANDA applications take less time than NDA applications, since the drug already has been approved in prescription form.
we are waiting on approved or withdrawn
yes i agree the delay is likely gsk spending millions to petition the fda against unnecessary market saturation
we lost so far to big pharma and that is nothing new
oh look the directors got their shares today under the 2016 equity incentive plan
which is designed to reward management and employees not directors!
they are a bunch of fraudsters plain and simple
yes the new promo plan should go into effect wed
expect some rosey pre q bs to be put out
happy 4th!
yes axim is not even worth $10m
the power of promos when the company is in on it
no value to the investment but a great trade
nemus will have its day in the sun and it will be closer to for real
axim will probably be back to $2 by sept
nmus might file an ind and report a planned p2 efficacy trial
ill keep loading the nmus
chico who? lol
no youll have to google fda anda review cycle and read up to understand what im talking about
basically the fda has 6 months from the time they begin their review of the application to make a response
jan 2015 in fluticare case
if they deny it for any reason and the co fixes the issue and resubmits it then the fda has another 6 months to respond
this can go back and forth until the fda finally approves it or sends a complete response letter or clr
a clr generally kills the submission and that is when most bios pr the info and the stock tanks
so im saying cos generally dont pr that they got a response from fda unless it is an end result response of either approval or clr
legitimate cos would offer an explanation of some kind to shareholders after 30 months but innv just does some other side deal
no way
go to jail go directly to jail do not pass go do not collect $200
i believe the co is only required to announce approval or abandonment of the application as an end result of failure to receive approval
most cos choose to report a crl in that event at the least
here is relevant info on fdas side of things
https://www.fda.gov/downloads/AboutFDA/Transparency/PublicDisclosure/GlossaryofAcronymsandAbbreviations/UCM211747.pdf
remember every time the fda returns the application and the co has to resubmit it starts a new 6 month cycle
i think innv has been through 3 or 4 of these and most recently enough to decide to make this dead mans deal with ww
water under the bridge now
i dont trust any aspect of this market company funders etc
just a thief among thieves
oh yea holdings still gets theirs
watch damaje really trim expenses this q and report .01
make it look like a big turnaround
market will fall for it and it will rise to .28
then the offsets will hit q3
ill be out of here and let the free shares ride
see adrocks titxf?
lmao
damnit was all set with 1200 cara to short today too
oh well my .32s sold here
set to reload at .29 so you can be guaranteed it wont go that low lol
thanks paul i never look at twitter pages otherwise
nice comeback today lets keep it going
ill chase for my reload i dont care
just get some action going on old girl
glta
i know its .09 down 20% today
what about expenses
do they have any of those?